London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Sterling Pharma Solutions, regarding the acquisition of Alcami’s Germantown, Wisconsin facility in the US.
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has announced its acquisition of Alcami’s Germantown, Wisconsin facility in the US.
The new facility will further bolster Sterling’s US presence and will provide additional capacity for customer API development and manufacturing projects, specifically those with complex and hazardous requirements.
The Germantown facility houses state-of-the-art cGMP development, scale-up and manufacturing facilities and has specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions
The acquisition follows Sterling’s sustained growth over the past four years, which has seen the company invest $46million into its service offering, including a recent $1.5million investment into the company’s Cary facility in the US.
Commenting on the announcement, Kevin Cook, CEO of Sterling Pharma Solutions, said: “We’re delighted to announce our acquisition of the Germantown facility in the US. This is the latest step of our strategic growth plans and will ensure we continue to provide a strong transatlantic API presence to support our customers.
The US market continues to be a key growth area for us. In addition to bolstering our API clinical and commercial manufacturing the Germantown facility has extensive expertise in handling high potency APIs, which will be a valuable addition to our organisation. We’re excited to welcome the Germantown team into the Sterling family.”
Walt Kaczmarek, Chief Executive Officer of Alcami said: “We want to thank the Germantown leadership team and employees for their dedication to the business and wish them success in the future.
Alcami has over 40 years of experience providing comprehensive drug product manufacturing and analytical testing services. This transaction continues our strategy to focus investments on our core service offerings.”
This announcement follows several expansion projects, including Alcami’s buildout of the sterile manufacturing site in Charleston, SC and the TriPharm acquisition completed in January 2020. Alcami is adding substantial sterile manufacturing and laboratory capacity with best-in-class facility and equipment design.
– Ends –
GHO Capital Partners LLP
T +44 20 3700 7440
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities in Europe, building market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to unlock value in a global system that demands the delivery of better, faster, more accessible healthcare . For further information, please visit www.ghocapital.com.
Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) and is one of the largest providers of small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. With over 50 years’ experience, the team can manage the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture.
In addition to the new Germantown facility Sterling also has its HQ in Dudley, Northumberland, UK, as well as laboratories and scale up facilities in Cary, North Carolina, US. For further information, please visit www.sterlingpharmasolutions.com.FacebookTwitterShareNews